CYTK CYTOKINETICS INC
Price Chart
Executive Summary
Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, with an option for an additional $97.5M. The filing comes on the same day as positive Q1 2026 results showing $4.8M in initial MYQORZO revenue and successful ACACIA-HCM trial results. Proceeds will fund the commercial launch and pipeline advancement, but the offering represents significant dilution.
Actionable Insight
Monitor pricing and final share count when the offering prices; the overallotment option could add up to $747.5M total. The positive Q1 launch metrics and ACACIA-HCM data provide fundamental support, but near-term selling pressure from the offering may weigh on the stock.
Key Facts
- Aggregate public offering price of $650,000,000 for common stock
- Underwriters have 30-day option to purchase additional $97,500,000 in shares
- As of March 31, 2026, net tangible book deficit was $(826.6) million, or $(6.65) per share
- 124,237,823 shares outstanding as of March 31, 2026
- Proceeds intended for MYQORZO commercial launch, pipeline advancement, and general corporate purposes
- Directors and executive officers subject to 45-day lock-up agreements
- Q1 2026 MYQORZO net product revenue of $4.8 million from initial partial quarter
- Cash and investments of approximately $1.1 billion as of March 31, 2026
Financial Impact
$650 million offering represents approximately 8% dilution at current market cap, with proceeds strengthening cash position for commercialization
Risk Factors
- Significant dilution to existing shareholders
- Execution risk in commercial launch of MYQORZO
- Potential downward price pressure from at-the-market sales by underwriters
- Continued cash burn from R&D and commercialization activities
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index-headers.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626.txt | 0001193125-26-206626 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
8d ago
|
Insider Cluster
| $70.91 $70.71 | ▼ −0.28% | ▲ +0.44% | $68.45 (−3.47%) |
|
May 20, 2026
20d ago
|
Insider Cluster
| $78.06 $76.94 | ▼ −1.43% | ▼ −1.88% | $68.45 (−12.31%) |
|
May 11, 2026
29d ago
|
Press Release
| $74.56 $74.81 | ▲ +0.34% | ▲ +0.47% | $68.45 (−8.19%) |
|
May 8, 2026
4w ago
|
Press Release
| $76.91 $74.56 | ▲ +3.06% | ▲ +3.29% | $68.45 (+11.00%) |
|
May 7, 2026
4w ago
|
Press Release
| $74.29 $76.91 | ▼ −3.53% | ▼ −2.70% | $68.45 (+7.86%) |
|
May 5, 2026
5w ago
|
424B5
| $74.84 $74.29 | ▼ −0.73% | ▼ −0.40% | $68.45 (−8.54%) |
|
May 5, 2026
5w ago
|
8-K
| $74.84 $74.84 | · 0.00% | ▲ +0.33% | $68.45 (−8.54%) |
|
May 5, 2026
5w ago
|
Press Release
| $77.09 $74.84 | ▼ −2.92% | ▼ −4.30% | $68.45 (−11.21%) |
|
May 5, 2026
5w ago
|
Insider Cluster
| $77.09 $74.84 | ▼ −2.92% | ▼ −4.30% | $68.45 (−11.21%) |
|
May 5, 2026
5w ago
|
Insider Cluster
| $74.84 $74.29 | ▼ −0.73% | ▼ −0.40% | $68.45 (−8.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access